抗内向整流钾通道4.1抗体作为多发性硬化可靠标志物未得到证实。
Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis.
作者信息
Nerrant Elodie, Salsac Céline, Charif Mahmoud, Ayrignac Xavier, Carra-Dalliere Clarisse, Castelnovo Giovanni, Goulabchand Radjiv, Tisseyre Julie, Raoul Cédric, Eliaou Jean-François, Labauge Pierre, Vincent Thierry
机构信息
Gui-de-Chauliac Hospital, France.
The Neuroscience Institute of Montpellier, Inserm UMR1051, Saint Eloi Hospital, France.
出版信息
Mult Scler. 2014 Nov;20(13):1699-703. doi: 10.1177/1352458514531086. Epub 2014 Apr 22.
BACKGROUND
auto-antibodies against the potassium channel inward rectifying potassium channel 4.1 (Kir4.1) have previously been identified in 46% of patients with multiple sclerosis (MS).
OBJECTIVES
to confirm these findings.
METHODS
we evaluated the presence of anti-Kir4.1 antibodies by enzyme-linked immunosorbent assay (ELISA) and immunofluorescence in 268 MS patients, 46 patients with other neurological diseases (OND) and 45 healthy controls.
RESULTS
anti-Kir4.1 antibodies were found in 7.5% of MS patients, 4.3% of OND patients and 4.4% of healthy controls. Immunofluorescence analysis did not identify any specific staining.
CONCLUSIONS
we confirmed the presence of anti-Kir4.1 antibodies in MS patients, but at a much lower prevalence than previously reported.
背景
先前在46%的多发性硬化症（MS）患者中发现了针对内向整流钾通道4.1（Kir4.1）的自身抗体。
目的
证实这些发现。
方法
我们通过酶联免疫吸附测定（ELISA）和免疫荧光法评估了268例MS患者、46例其他神经系统疾病（OND）患者和45名健康对照者中抗Kir4.1抗体的存在情况。
结果
在7.5%的MS患者、4.3%的OND患者和4.4%的健康对照者中发现了抗Kir4.1抗体。免疫荧光分析未发现任何特异性染色。
结论
我们证实了MS患者中存在抗Kir4.1抗体，但患病率远低于先前报道。
Zotero 插件